Atlas Trials

A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL

Clinical trial NCT07609823 · RECRUITING

Trial details

NCT number
NCT07609823
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Start date
2026-07-14
Primary completion
2028-03-30
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.